Overview

A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

Status:
Recruiting
Trial end date:
2024-08-20
Target enrollment:
Participant gender:
Summary
This trial is to further study the safety and effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work.
Phase:
Phase 2
Details
Lead Sponsor:
Cure&Sure Biotech Co., LTD
Collaborators:
Beijing Tiantan Hospital
Shenzhen Second People's Hospital
Treatments:
Temozolomide